Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 49% in Phase 3 Trial

A Phase 3 trial published in the New England Journal of Medicine shows a personalized mRNA vaccine cut the risk of melanoma recurrence or death by 49 percent compared with standard immunotherapy alone.

All 1,137 participants had high-risk cutaneous melanoma that had been completely removed by surgery and received pembrolizumab, the immunotherapy that blocks one of the brakes cancer uses to restrain the immune system. Two-thirds were randomly assigned to also receive intismeran autogene, an individually manufactured messenger RNA therapy; the rest received a placebo.

At 24 months, 82.2 percent of patients who received the combination remained alive and free of recurrence, versus 70 percent in the pembrolizumab-plus-placebo group, according to El Español. Distant metastases were also less frequent: 88.5 percent of the combination group remained free of them at two years, compared with 80.2 percent of controls.

A Vaccine Made From Each Patient's Cancer Cut Melanoma Risk 42% — Max Daily News

Personalizing cancer treatment usually means analyzing a biomarker and choosing among existing drugs. Here, a new product is built for each patient. The tumor is studied, mutations capable of distinguishing malignant cells from healthy ones are identified, and up to 34 of those signals are selected. A messenger RNA carrying that information is then constructed to teach the immune system what to hunt.

“We are used to thinking that a vaccine is manufactured by the millions and then administered to different people. The one I am talking to you about today works the other way around: first you have to know someone’s cancer and, starting from their own mutations, manufacture a specific treatment; I would say: personalized,” the article says.

Serious or clinically significant adverse events occurred more often with the individualized strategy: 23.6 percent versus 20.3 percent. The trial has not yet demonstrated an improvement in overall survival, and follow-up continues. “It is still unknown whether those who received the combination will live more years, because the trial has not yet demonstrated an improvement in overall survival and follow-up continues,” the report says.

The New England Journal of Medicine, which published this Phase 3 trial, began in January 1812 as the New England Journal of Medicine and Surgery and Collateral Branches of Medical Science, a quarterly started by Boston physicians John Collins Warren and James Jackson. In 1828, its editors purchased the weekly Boston Medical Intelligencer for $600 and merged the two to form the Boston Medical and Surgical Journal, shifting to weekly publication.

The Massachusetts Medical Society acquired the journal for US$1 in 1921, renaming it The New England Journal of Medicine in 1928; its logo still bears the founding dates 1812, 1823, 1828, and 1928. In November 1846, the journal published Henry Jacob Bigelow’s report on the first public demonstration of ether anesthesia, a landmark in surgical history.

Producing a bespoke therapy requires obtaining sufficient tissue, sequencing it, selecting the appropriate neoantigens, designing the RNA, manufacturing it with guarantees, and delivering it to the hospital in time.

“That means money, infrastructure and access. A medicine manufactured for each patient may represent perhaps the most refined expression of modern oncology and, at the same time, create a new frontier between those who can receive it and those who are left out,” the article concludes.

Photo of author

Health Desk

Health Desk at Archyde.

SHAREit Legacy Windows 7 Installer, Modern Client Persist for Cross-Platform Transfers